Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.
Voyager Therapeutics has signed another big pharma partner for its TRACER adeno-associated virus (AAV) vector technology, designed to improve the safety of gene therapies, with Novartis tak
Biogen has made a $15 million investment in digital health company TheraPanacea, which will go towards a project to find digital health tools aimed at neurological diseases.
